This report contains detailed information about the company's business finances and management.
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 63.49 | 0.02 0.03% | 3.09% | 1,833,232 | 3.1M |
Editor Note: For more information about this release, please scroll to bottom LONDON, July 21, 2014 /PRNewswire/ -- On Friday, July 18, 2014, the NASDAQ Composite ended at 4,432.15, up 1.57%, the Dow Jones Industrial Average finished the day 0.73% higher at 17,100.18, and the S&P; 500 closed at 1,978.22, up 1.03%. The gains were broad based as all the ten sectors ended the session in positive. The S&P; 500 Health Care Sector Index ended the day at 710.68, up 1.63%, and the index has advanced 1.14% in the last one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Merck & Company Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Eli Lilly & Company (NYSE: LLY). Free research on these five companies can be accessed at:
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
CORAL SPRINGS, Florida, July 16, 2014 /PRNewswire/ -- Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company's products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company's new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.
| Bid/Size | Ask/Size |
|---|---|
| -- / -- | -- / -- |
| Price Open | Previous Close |
|---|---|
| 63.00 | 63.47 |
| Day High | Day Low |
|---|---|
| 63.54 | 62.75 |
| 52wk High/Date | 52wk Low/Date |
|---|---|
| 63.54 / 7/21/2014 | 47.53 / 10/9/2013 |
| % off 52wk High | % off 52wk Low |
|---|---|
| -0.08% | 33.58% |
| Beta (5 Yr) | Market Capitalization |
|---|---|
| 0.4 | 71.1B Large Cap |
| Shares Outstanding | Volatility Avg |
|---|---|
| 1.1B | 17.00 |
| EPS(TTM) | P/E Ratio |
|---|---|
| 3.58 | 17.8 |
| Dividend Announcement | Dividend Yield |
|---|---|
| 6/16/2014 | 3.09% |
| Ex-Date | Date of Record |
|---|---|
| 8/13/2014 | 8/15/2014 |
| Payable | Payable Date |
|---|---|
| 0.49 - QRTR | 9/10/2014 |
| Peers | |
|---|---|
LLY Eli Lilly and Co | 24.45% |
Johnson & Johnson | 11.15% |
Pfizer Inc. | 0.33% |
Merck & Co., Inc. | 16.56% |
Abbott Laboratories | 11.48% |
LLY Eli Lilly and Co | 3.09% |
Johnson & Johnson | 2.75% |
Pfizer Inc. | 3.38% |
Merck & Co., Inc. | 3.02% |
Abbott Laboratories | 2.06% |
LLY Eli Lilly and Co | 0.03% |
Johnson & Johnson | -0.44% |
Pfizer Inc. | -1.07% |
Merck & Co., Inc. | -0.60% |
Abbott Laboratories | -0.07% |